Active, Not Recruiting
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
NCT04079712
- Conditions
- Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +20 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States